DR. FRANK LEE SCHWARTZ, M.D.
Osteopathic Medicine at Ann St, Parkersburg, WV
License number
West Virginia 35058123
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
604 Ann St, Parkersburg, WV 26101
Phone
(304) 424-2400
(304) 865-5036 (Fax)
(304) 865-5036 (Fax)
Personal information
See more information about FRANK LEE SCHWARTZ at radaris.comName
Address
Phone
1100 46Th St, Vienna, WV 26105
Professional information
Methods And Compositions For The Treatment Of Malignant Melanoma, Breast, Prostate, Colon, Papillary Thyroid And Pancreatic Cancer
US Patent:
2010000, Jan 7, 2010
Filed:
Oct 1, 2008
Appl. No.:
12/286880
Inventors:
Leonard D. Kohn - Woodinville WA, US
Douglas J. Goetz - Athens OH, US
Kelly D. McCall - Shade OH, US
Anthony Schwartz - Vienna WV, US
Frank Schwartz - Vienna WV, US
Ramiro Malgor - Athens OH, US
Glorglo Napolitano - Montesilvano (PE), IT
Cesidio Giullant - Roccamonce, IT
Douglas J. Goetz - Athens OH, US
Kelly D. McCall - Shade OH, US
Anthony Schwartz - Vienna WV, US
Frank Schwartz - Vienna WV, US
Ramiro Malgor - Athens OH, US
Glorglo Napolitano - Montesilvano (PE), IT
Cesidio Giullant - Roccamonce, IT
International Classification:
A61K 31/4164, C12N 5/06
US Classification:
514396, 435375
Abstract:
It is now recognized that chronic inflammation is an important risk factor for the development of cancer. The proinflammatory cytokine IL-6 is implicated in cancer because it is important for the activation of STAT, a key regulator of cancer growth, survival, metastasis, immune evasion and angiogenesis. Increased IL-6 and Stat-3 exists in vitro in pancreatic cancer, malignant melanoma, papillary thyroid cancer, breast cancer, colon cancer, and prostate cancer cells with high basal expression of Toll-like receptor 3 (TLR3) and Wnt5a. IL6/STAT3 activation, mediated by overexpressed TLR3 signaling, appears important in the tumor growth process, it may increase Wnt5a signaling, and be associated with increased cellular growth and migration. Using a novel inhibitor of pathologic TLR3 signaling (5-phenylmethimazole [C10]) we have demonstrated decreases in these markers plus suppression of cell growth and migration in human pancreatic cancer, malignant melanoma, papillary thyroid cancer, breast cancer, colon cancer, and prostate cancer cells.
System And Method For Managing Diabetes
US Patent:
2008022, Sep 11, 2008
Filed:
Feb 15, 2008
Appl. No.:
12/032021
Inventors:
Cynthia Robin Marling - Athens OH, US
Frank Lee Schwartz - Vienna WV, US
Frank Lee Schwartz - Vienna WV, US
Assignee:
OHIO UNIVERSITY - Athens OH
International Classification:
G09B 23/28, A61B 19/00, A61K 9/22
US Classification:
434262, 128898, 6048901
Abstract:
A system and method are provided for automatically analyzing data for a patient with type 1 diabetes on insulin pump therapy and recommending appropriate therapeutic adjustments to the patient. In the system and the method, case-based reasoning is used as a primary reasoning modality in determining the therapeutic adjustments.